Open access
Open access
Powered by Google Translator Translator

RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.

10 Feb, 2022 | 09:56h | UTC

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.